Abstract: A dispensing apparatus for a liquid product, the apparatus comprising a) a housing (2) or frame (3), b) a receptacle (4) for the liquid with a feed nozzle (4a) arranged substantially stationary with respect to the housing or frame, c) a dosing chamber (11) having an orifice (11a), d) a mechanism arranged to allow at least ejection of liquid through the orifice and e) a through passage (7) arranged to allow the ejected liquid to pass in a direction different from the feed nozzle or opening.
Type:
Grant
Filed:
September 8, 2003
Date of Patent:
July 4, 2006
Assignee:
Agouron Pharmaceuticals, Inc.
Inventors:
Bohdan Pavlu, Hans Himbert, Christian Péclat, Emmanuel Gremion, Daniel Siegfried, Alain Saurer, Joel Fontannaz
Abstract: An eye fluid applicator comprising a) a hand grip part having a distal end and a proximal end, the distal end and the proximal end defining a axis therebetween and a distal direction and a proximal direction along said axis, b) a container, or a seat for a container, having a bottle part and a delivery orifice for delivery of a stream or drops, the orifice defining a fluid delivery axis and a fluid delivery direction, along said axis, from the bottle through the orifice, the container being arranged with its orifice closer to the proximal end than the distal end, and c) an eye cup part having a rim and a cavity, the rim defining a contact plane, a contact axis normal to said contact plane and a contact direction, along said contact axis, from the cavity towards the rim, the eye cup being arranged at the orifice and the proximal direction of the hand grip and the contact direction of the eye cup forming an acute angle therebetween.
Type:
Grant
Filed:
May 21, 2002
Date of Patent:
June 20, 2006
Assignee:
Agouron Pharmaceuticals , Inc.
Inventors:
Maria Benktzon, Henric Bjarke, Carl-Göran Crafoord, Hans Himbert, Stig Mannberg, Ann-Marie Svensson, Jonas Törnsten
Abstract: Indazole compounds that modulate and/or inhibit the ophthalmic diseases and the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating ophthalmic diseases and cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.
Type:
Grant
Filed:
December 15, 2003
Date of Patent:
May 30, 2006
Assignee:
Agouron Pharmaceuticals, Inc.
Inventors:
Allen J. Borchardt, Robert Steven Kania, Cynthia L. Palmer
Abstract: The invention relates to compounds represented by the formula I and to prodrugs or metabolites thereof, or pharmaceutically acceptable salts or solvates of said compounds, said prodrugs, and said metabolites, wherein Z, Y, R11 and R14, R15, R16, and R17 are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formula I and to methods of treating hyperproliferative disorders in a mammal by administering the compounds of formula I.
Type:
Grant
Filed:
March 9, 2004
Date of Patent:
May 16, 2006
Assignee:
Agouron Pharmaceuticals, Inc.
Inventors:
Michael Collins, Stephan Cripps, Judith Deal, Robert Steven Kania, Jihong Lou, Mingying He, Cynthia Louise Palmer, William Henry Romines, III, Ru Zhou
Abstract: This invention describes a convenient method for the preparation and use of a ruthenium catalyst for a chiral reduction of ketones and imines.
Abstract: 3,5 disubstituted indazole compounds that modulate and/or inhibit cell proliferation, such as the activity of protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating CDK dependent diseases to modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.
Type:
Grant
Filed:
June 10, 2004
Date of Patent:
March 7, 2006
Assignee:
Agouron Pharmaceuticals, Inc.
Inventors:
Susan Elizabeth Kephart, Indrawan James McAlpine, Siegfried Heinz Reich
Abstract: Beta-carboline hydroxamic acid compounds represented by formula (I) are described. The beta-carboline hydroxamic acid compounds and compositions containing those compounds may be used to inhibit or modulate the activity of HIV integrase enzyme and to treat HIV integrase-mediated diseases and conditions.
Type:
Grant
Filed:
January 26, 2004
Date of Patent:
February 21, 2006
Assignee:
Agouron Pharmaceuticals, Inc.
Inventors:
Atsuo Kuki, Xinqiang Li, Michael Bruno Plewe, Hai Wang, Junhu Zhang
Abstract: Peptido and peptidomimetic compounds of the formula: wherein the formula variables are as defined in the disclosure, advantageously inhibit or block the biological activity of the picornaviral 3C protease. These compounds, as well as pharmaceutical compositions containing these compounds, are useful for treating patients or hosts infected with one or more picornaviruses, such as RVP. Intermediates and synthetic methods for preparing such compounds are also provided.
Type:
Grant
Filed:
November 6, 2002
Date of Patent:
February 7, 2006
Assignee:
Agouron Pharmaceuticals, Inc.
Inventors:
Peter Scott Dragovich, Stephen Evan Webber, Thomas Jay Prins, Ru Zhou, Joseph Timothy Marakovits, Theodore O. Johnson, Jr.
Abstract: The invention relates to compounds of the formulas 1 and 2 and to prodrugs thereof, pharmaceutically acceptable salts or solvates of said compounds or said prodrugs, wherein X, R1 and R11 are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formulas 1 and 2 and to methods of treating hyperproliferative disorders in a mammal by administering the compounds of formulas 1 and 2.
Type:
Grant
Filed:
June 20, 2002
Date of Patent:
February 7, 2006
Assignee:
Agouron Pharmaceuticals, Inc.
Inventors:
Christopher Autry, Michael J. Luzzio, Matthew A. Marx
Abstract: Compounds of the formula: where the formula variables are as defined in the disclosure, advantageously inhibit or block the biological activity of the picomaviral 3C protease. These compounds, as well as pharmaceutical compositions containing these compounds, are useful for treating patients or hosts infected with one or more picornaviruses, such as RVP. Intermediates and synthetic methods for preparing such compounds are also described.
Type:
Grant
Filed:
July 23, 2003
Date of Patent:
January 24, 2006
Assignee:
Agouron Pharmaceuticals, Inc.
Inventors:
Ye Hua, Hiep The Luu, Fora P. Chan, Theodore O. Johnson, Jr., Siegfried Heinz Reich, Donald James Skalitzky, Yi Yang, Thomas F. Hendrickson, Shao Song Chu, Brian Walter Eastman
Abstract: The invention provides compounds of formula I, R1—OP(O)(OH)2??I wherein R1 represents the non-hydroxy portion of a triazole antifungal compound of the type comprising a tertiary hydroxy group; or a pharmaceutically acceptable sat thereof. The compounds of the invention are useful in the treatment of fungal infections, and have good aqueous solubility.
Type:
Grant
Filed:
March 26, 2004
Date of Patent:
December 20, 2005
Assignee:
Agouron Pharmaceuticals, Inc.
Inventors:
Stuart Green, Peter T. Stephenson, Martha H. Murtiashaw, Charles W. Murtiashaw
Abstract: This invention relates to a process for the synthesis of enantiomerically enriched (1S,4R) 1-acetoxy-4-hydroxycyclopent-2-ene of Formula I, a compound useful as an intermediate in the synthesis of prostaglandins and prostanoids.
Abstract: Protein kinase, such as CHK-1, inhibiting tricyclic compounds of the following formula (wherein R2, R3 and R4 are as defined in the specification) pharmaceutical compositions containing effective amounts of said compounds or their salts are useful as a single agent or in combination with an anti-neoplastic agent or therapeutic radiation having an anti-neoplastic effect for treating diseases or conditions such as cancers.
Type:
Grant
Filed:
January 9, 2004
Date of Patent:
November 22, 2005
Assignee:
Agouron Pharmaceuticals Inc.
Inventors:
Suzanne Benedict, Michael Bennett, Sacha Ninkovic, Min Teng, Yuanjin Rui, Fen Wang, Yong Wang, Jinjiang Zhu
Abstract: Pyrazole compounds represented by the formula: are described. The pyrazole compounds and pharmaceutical compositions containing them may be used in inhibiting ERAB or HADH2 activity and in treating ERAB, HADH2 or amyloid-? mediated diseases and conditions.
Type:
Grant
Filed:
August 17, 2001
Date of Patent:
November 15, 2005
Assignee:
Agouron Pharmaceuticals, Inc.
Inventors:
Melwyn A. Abreo, Jerry J. Meng, Charles S. Agree
Abstract: Compounds of the formula: where the formula variables are as defined herein, are disclosed that advantageously inhibit or block the biological activity of the HIV protease. These compounds, as well as pharmaceutical compositions containing these compounds, are useful for treating patients or hosts infected with the HIV virus. Intermediates and synthetic methods for preparing such compounds are also described.
Type:
Grant
Filed:
June 11, 2002
Date of Patent:
October 11, 2005
Assignee:
Agouron Pharmaceuticals, Inc.
Inventors:
Stacie S. Canan Koch, Therese N. Alexander, Mark Barvian, Gary Bolton, Frederick Earl Boyer, Jr., Benjamin J. Burke, Tod Holler, Tanya M. Jewell, Vara Prasad Josyula, David J. Kucera, Maria Angelica Linton, Jeffrey J. Machak, Lennert J. Mitchell, Jr., Sean T. Murphy, Siegfried H. Reich, Donald J. Skalitzky, John H. Tatlock, Michael D. Varney, Scott C. Virgil, Stephen E. Webber, Stephen T. Worland, Michael Melnick
Abstract: This invention relates to pyrazole derivatives of formula (I) or pharmaceutically acceptable salts, solvates or derivative thereof, wherein R1 to R4, n W, X and Y are defined in the description, and to processes for the preparation thereof, intermediates used in their preparation of, compositions containing them and the uses of such derivatives. The compounds of the present invention bind to the enzyme reverse transcriptase and are modulators, especially inhibitors thereof. As such the compounds of the present invention are useful in the treatment of a variety of disorders including those in which the inhibition of reverse transcriptase is implicated. Disorders of interest include those caused by Human Immunodificiency Virus (HIV) and genetically related retroviruses, such as Acquired Immune Deficiency Syndrome (AIDS).
Type:
Grant
Filed:
September 23, 2003
Date of Patent:
August 23, 2005
Assignee:
Agouron Pharmaceuticals, Inc.
Inventors:
David A. Price, Matthew D. Selby, Paul A. Stupple
Abstract: Indazole compounds that modulate and/or inhibit cell proliferation, such as the activity of protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating, e.g., kinases-dependent diseases to modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.
Type:
Grant
Filed:
November 8, 2002
Date of Patent:
July 19, 2005
Assignee:
Agouron Pharmaceuticals, Inc.
Inventors:
Siegfried Heinz Reich, Ted Michael Bleckman, Susan Elizabeth Kephart, William Henry Romines, Michael B. Wallace
Abstract: Peptido and peptidomimetic compounds of the formula: wherein the formula variables are as defined in the disclosure, advantageously inhibit or block the biological activity of the picornaviral 3C protease. These compounds, as well as pharmaceutical compositions containing these compounds, are useful for treating patients or hosts infected with one or more picornaviruses, such as RVP. Intermediates and synthetic methods for preparing such compounds are also provided.
Type:
Grant
Filed:
January 5, 1999
Date of Patent:
June 14, 2005
Assignee:
Agouron Pharmaceuticals, Inc.
Inventors:
Peter Scott Dragovich, Stephen Evan Webber, Thomas Jay Prins, Ru Zhou, Joseph Timothy Marakovits, Theodore O. Johnson, Jr., Jayashree Girish Tikhe
Abstract: Non-peptide GnRH agents capable of inhibiting the effect of gonadotropin-releasing hormone are described. Such compounds and their pharmaceutically acceptable salts, prodrugs, and active metabolites are suitable for treating mammalian reproductive disorders and steroid hormone-dependent tumors as well as for regulating fertility, where suppression of gonadotropin release is indicated. Methods for synthesizing the compounds and intermediates useful in their preparation are also described.
Type:
Grant
Filed:
June 11, 2003
Date of Patent:
June 7, 2005
Assignees:
Agouron Pharmaceuticals, Inc., Pfizer Inc.
Inventors:
Mark B. Anderson, Lance Christopher Christie, Quyen-Quyen Thuy Do, Jun Feng, Yufeng Hong, Haitao Li, Ved P. Pathak, Ranjan Jagath Rajapakse, Eric T. Sun, Eileen Valenzuela Tompkins